Jump to content

Deferoxamine: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
No edit summary
British usage; add ref
Line 23: Line 23:
'''Deferoxamine''' (also known as '''desferrioxamine''', '''desferoxamine''', '''DFO''', '''DFOA''' or '''desferal''') is a [[chelating agent]] used to remove excess [[iron]] from the body. It acts by binding free iron in the bloodstream and enhancing its elimination in the [[urine]]. By removing excess iron, the agent reduces the damage done to various organs and tissues, such as the [[liver]].
'''Deferoxamine''' (also known as '''desferrioxamine''', '''desferoxamine''', '''DFO''', '''DFOA''' or '''desferal''') is a [[chelating agent]] used to remove excess [[iron]] from the body. It acts by binding free iron in the bloodstream and enhancing its elimination in the [[urine]]. By removing excess iron, the agent reduces the damage done to various organs and tissues, such as the [[liver]].


Defiroxamine is used to treat acute [[iron poisoning]], especially in small children. Treatment with this agent is also frequently necessary to treat [[hemochromatosis]], a disease of iron accumulation that can be either genetic or acquired. Acquired [[hemochromatosis]] is common in patients with certain types of chronic [[anemia]] (e.g. [[thalassemia]] and [[myelodysplastic syndrome]]) who require many [[blood transfusion]]s, which can greatly increase the amount of iron in the body. Administration for chronic conditions is generally accomplished by [[subcutaneous injection]] (SQ) over a period of 8-12 hours daily. Administration of deferoxamine after acute intoxication may color the urine a pinkish red, a phenomenon termed "'vin rose'' urine".
Deferoxamine is used to treat acute [[iron poisoning]], especially in small children. Treatment with this agent is also frequently necessary to treat [[hemochromatosis]], a disease of iron accumulation that can be either genetic or acquired. Acquired [[hemochromatosis]] is common in patients with certain types of chronic [[anemia]] (e.g. [[thalassemia]] and [[myelodysplastic syndrome]]) who require many [[blood transfusion]]s, which can greatly increase the amount of iron in the body. Administration for chronic conditions is generally accomplished by [[subcutaneous injection]] (SQ) over a period of 8-12 hours daily. Administration of deferoxamine after acute intoxication may color the urine a pinkish red, a phenomenon termed "'vin rose'' urine".


Apart from in iron toxicity, deferoxamine is also used to treat [[aluminium]] toxicity (an excess of aluminium in the body) in certain patients.
Apart from in iron toxicity, deferoxamine is also used to treat [[aluminium]] toxicity (an excess of aluminium in the body) in certain patients.


A study published in January 2008 suggests that deferoxamine can be used to speed [[fracture healing]].<ref>[http://www.sciencedaily.com/releases/2008/01/080110085148.htm Science Daily Report]</ref>
A study published in January 2008 suggests that deferoxamine can be used to speed [[fracture healing]].<ref>[http://www.sciencedaily.com/releases/2008/01/080110085148.htm Science Daily Report]</ref>

In Britain, the Mesilate salt is generally used.


==See also==
==See also==
* [[Chelation therapy]]
* [[Chelation therapy]]

{{BNF}} p.32


{{Chelating agents}}
{{Chelating agents}}

Revision as of 21:28, 21 August 2008

Deferoxamine
Clinical data
Pregnancy
category
  • ?
Routes of
administration
Oral, IV, IM, SQ
ATC code
Legal status
Legal status
  • ?
Pharmacokinetic data
Bioavailability?
Metabolism?
Elimination half-life6 hours
Excretion?
Identifiers
  • N'-[5-(acetyl-hydroxy-amino)pentyl]-N-
    [5-[3-(5-aminopentyl-hydroxy-carbamoyl)
    propanoylamino]pentyl]-N-hydroxy-butane
    diamide
CAS Number
PubChem CID
DrugBank
CompTox Dashboard (EPA)
ECHA InfoCard100.000.671 Edit this at Wikidata
Chemical and physical data
FormulaC25H48N6O8
Molar mass560.684 g/mol g·mol−1

Deferoxamine (also known as desferrioxamine, desferoxamine, DFO, DFOA or desferal) is a chelating agent used to remove excess iron from the body. It acts by binding free iron in the bloodstream and enhancing its elimination in the urine. By removing excess iron, the agent reduces the damage done to various organs and tissues, such as the liver.

Deferoxamine is used to treat acute iron poisoning, especially in small children. Treatment with this agent is also frequently necessary to treat hemochromatosis, a disease of iron accumulation that can be either genetic or acquired. Acquired hemochromatosis is common in patients with certain types of chronic anemia (e.g. thalassemia and myelodysplastic syndrome) who require many blood transfusions, which can greatly increase the amount of iron in the body. Administration for chronic conditions is generally accomplished by subcutaneous injection (SQ) over a period of 8-12 hours daily. Administration of deferoxamine after acute intoxication may color the urine a pinkish red, a phenomenon termed "'vin rose urine".

Apart from in iron toxicity, deferoxamine is also used to treat aluminium toxicity (an excess of aluminium in the body) in certain patients.

A study published in January 2008 suggests that deferoxamine can be used to speed fracture healing.[1]

In Britain, the Mesilate salt is generally used.

See also

p.32